Compare CBIO & ASLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBIO | ASLE |
|---|---|---|
| Founded | 2003 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Industrial Specialties |
| Sector | | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 389.7M | 356.2M |
| IPO Year | N/A | N/A |
| Metric | CBIO | ASLE |
|---|---|---|
| Price | $10.83 | $7.39 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 2 |
| Target Price | ★ $27.17 | $7.00 |
| AVG Volume (30 Days) | 142.5K | ★ 256.0K |
| Earning Date | 02-23-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.11 |
| Revenue | N/A | ★ $339,090,000.00 |
| Revenue This Year | N/A | $1.35 |
| Revenue Next Year | N/A | $19.09 |
| P/E Ratio | ★ N/A | $67.84 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.81 | $5.56 |
| 52 Week High | $21.40 | $9.12 |
| Indicator | CBIO | ASLE |
|---|---|---|
| Relative Strength Index (RSI) | 37.86 | 50.39 |
| Support Level | $10.56 | $7.30 |
| Resistance Level | $14.71 | $7.68 |
| Average True Range (ATR) | 1.01 | 0.24 |
| MACD | -0.07 | -0.04 |
| Stochastic Oscillator | 6.14 | 15.97 |
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
AerSale Corp is an integrated, diversified leader in aviation aftermarket products and services. It specializes in the sale, lease, and exchange of used aircraft, engines, and components, in addition to providing a broad range of maintenance, repair, and overhaul, and engineering services for commercial aircraft and components. The company operating segment includes Asset Management Solutions and TechOps. It generates maximum revenue from the Asset Management Solutions segment.